Zanubrutinib for DLBCL with specific genetic changes
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a type of lymphoma called DLBCL.
- Your tumor must have a specific genetic change (MYD88 L265P, CD79B, or NOTCH1) or be positive for CD5 (a marker on the cancer cells).
- You can have had no more than 1 cycle of R-CHOP chemotherapy before starting this trial.
- You need to have measurable disease visible on a PET/CT scan.
- Your kidneys, liver, and blood counts need to be working well enough (your doctor will check this with blood tests).
- You must not have certain serious heart conditions, active infections, or other cancers treated within the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This trial tests a maintenance therapy with zanubrutinib in newly diagnosed DLBCL patients who have responded to initial treatment but couldn't tolerate standard chemotherapy. The goal is to prevent the cancer from coming back.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.